C. Paronis

发表

Measuring the reinforcing strength of abused drugs.

J. Bergman, C. Paronis, 2006, Molecular interventions.

Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment

Sarah L. Withey, R. Spealman, J. Bergman, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Buprenorphine and Opioid Antagonism, Tolerance, and Naltrexone-Precipitated Withdrawal

J. Bergman, C. Paronis, 2011, Journal of Pharmacology and Experimental Therapeutics.

The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of “Tail Wags Dog” Experiments

Sarah L. Withey, S. Hassan, K. Rice, 2020, Molecules.

NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques

R. Depoortère, A. Newman-Tancredi, R. I. Desai, 2022, Neuropharmacology.

Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.

Anna L. Bowman, S. Nikas, S. O. Alapafuja, 2010, Journal of medicinal chemistry.

Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.

S. Nikas, A. Makriyannis, J. Bergman, 2016, Journal of medicinal chemistry.

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538

A. Makriyannis, J. Bergman, C. Paronis, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Modulating GABA modulators

C. Paronis, 2006, British journal of pharmacology.

A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists

D. Selley, K. Rice, T. Prisinzano, 2022, Molecules.

ArticleA Journey Through Diastereomeric Space: The Design

D. Selley, K. Rice, T. Prisinzano, 2022 .

Evidence for spontaneous cannabinoid withdrawal in mice

S. Nikas, J. Bergman, Ioannis Papanastasiou, 2021, Behavioural pharmacology.

Diuretic Effects of Cannabinoids

S. Nikas, A. Makriyannis, G. Thakur, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Cannabinoid mediated diuresis in mice

Rishi Sharma, A. Makriyannis, G. Thakur, 2011 .

ANTAGONISM OF THE DISCRIMINATIVE STIMULUS EFFECTS OF MIDAZOLAM BY FLUMAZENIL AND BRETAZENIL IN SQUIRREL MONKEYS

C. Paronis, 1998 .

Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice

A. Makriyannis, G. Thakur, S. Gatley, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Sarah L. Withey, J. Bergman, C. Paronis, 2018, The journal of pain : official journal of the American Pain Society.

Cannabinoid-induced lower lip retraction in rats

Rishi Sharma, S. Nikas, A. Makriyannis, 2018, Psychopharmacology.

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties

A. Makriyannis, G. Thakur, J. Bergman, 2008, Physiology & Behavior.

Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.

C. Paronis, S. Holtzman, 1992, The Journal of pharmacology and experimental therapeutics.

Evaluation of the Reinforcing Effects of Monoamine Reuptake Inhibitors Under a Concurrent Schedule of Food and I.V. Drug Delivery in Rhesus Monkeys

J. Bergman, C. Paronis, M. Gasior, 2005, Neuropsychopharmacology.

Different types of GABAA receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys

J. Bergman, C. Paronis, J. Cook, 2001, Psychopharmacology.

Cannabinoid-induced lower lip retraction in rats

Rishi Sharma, S. Nikas, A. Makriyannis, 2018, Psychopharmacology.

Naltrexone in vivo protects μ receptors from inactivation by β-funaltrexamine, but not κ receptors from inactivation by nor-binaltorphimine

C. Paronis, S. Holtzman, A. B. Waddell, 1993, Pharmacology Biochemistry and Behavior.

Acute dependence on, but not tolerance to, heroin and morphine as measured by respiratory effects in rhesus monkeys.

J. Woods, C. Paronis, S. Kishioka, 2000, European journal of pharmacology.

Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys

C. Paronis, M. Delatte, 2008, Psychopharmacology.

Behavioral Pharmacology of AR-A000002, a Novel, Selective 5-Hydroxytryptamine1B Antagonist

T J Hudzik, J. Evenden, C. Ryan, 2003, Journal of Pharmacology and Experimental Therapeutics.

Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking.

J. Kassel, L. Stroud, C. Paronis, 2003, Psychological bulletin.

Diuretic effects of cannabinoid agonists in mice.

Rishi Sharma, A. Makriyannis, G. Thakur, 2013, European journal of pharmacology.

Possible Efficacy Related Differences Among Cannabinoid Agonists

A. Makriyannis, J. Bergman, C. Paronis, 2013 .

Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.

J. Woods, C. Paronis, 1997, European journal of pharmacology.

Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses

T. Prisinzano, J. Bergman, C. Paronis, 2021, Pharmacology Biochemistry and Behavior.

Novel adamantyl cannabinoids as CB1 receptor probes.

Anna L. Bowman, M. Caron, J. Deschamps, 2013, Journal of medicinal chemistry.

Altered sleep during spontaneous cannabinoid withdrawal in male mice

S. Nikas, W. Carlezon, J. Bergman, 2022, Behavioural pharmacology.

Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys.

J. Woods, C. Paronis, J. Lewis, 2000, European journal of pharmacology.

Discriminative-Stimulus Effects of Synthetic Cathinones in Squirrel Monkeys

T. Prisinzano, J. Bergman, C. Paronis, 2021, The international journal of neuropsychopharmacology.

Pharmacological characterization of the effects of dopamine D1 agonists on eye blinking in rats

J. Neumeyer, J. Bergman, C. Paronis, 2007, Behavioural pharmacology.

Ventilation in morphine-maintained rhesus monkeys. II: Tolerance to the antinociceptive but not the ventilatory effects of morphine.

J. Woods, C. Paronis, 1997, The Journal of pharmacology and experimental therapeutics.

Apparent pA2 value of naltrexone is not changed in rats following continuous exposure to morphine or naloxone.

C. Paronis, S. Holtzman, 1992, Life sciences.

Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists

C. Paronis, S. Holtzman, 1994, Psychopharmacology.

Controlled-deactivation cannabinergic ligands.

S. Nikas, A. Makriyannis, J. Wood, 2013, Journal of medicinal chemistry.

Monoaminergic Psychomotor Stimulants: Discriminative Stimulus Effects and Dopamine Efflux

J. Bergman, C. Paronis, R. Desai, 2010, Journal of Pharmacology and Experimental Therapeutics.

Effects of cocaine under concurrent fixed ratio schedules of food and IV drug availability: a novel choice procedure in monkeys

J. Bergman, C. Paronis, M. Gasior, 2002, Psychopharmacology.

Ethanol self-administration in rats responding under concurrent schedules for milk or ethanol plus milk

C. Paronis, 2013, Behavioural pharmacology.

Modification by Dopaminergic Drugs of Choice Behavior under Concurrent Schedules of Intravenous Saline and Food Delivery in Monkeys

J. Bergman, C. Paronis, M. Gasior, 2004, Journal of Pharmacology and Experimental Therapeutics.

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse

K. Bui, C. Paronis, M. Pietras, 2014, Pharmacology Biochemistry and Behavior.

Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.

C. Paronis, S. Holtzman, J. Adams, 1990, The Journal of pharmacology and experimental therapeutics.

Ventilation in morphine-maintained rhesus monkeys. I: Effects of naltrexone and abstinence-associated withdrawal.

J. Woods, C. Paronis, 1997, The Journal of pharmacology and experimental therapeutics.

Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys.

J. Neumeyer, J. Bergman, C. Paronis, 2007, European journal of pharmacology.

Apparent pA2 values of benzodiazepine antagonists and partial agonists in monkeys.

J. Bergman, C. Paronis, 1999, The Journal of pharmacology and experimental therapeutics.

Increased analgesic potency of mu agonists after continuous naloxone infusion in rats.

C. Paronis, S. Holtzman, 1991, The Journal of pharmacology and experimental therapeutics.

Behavioral effects of the R-(+)- and S-( − ) enantiomers of the D 1 -like partial receptor agonist SKF 83959 in monkeys

J. Neumeyer, C. Paronis, R. Desai, 2008 .

Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys.

N. Knebel, J. Bergman, S. Yasar, 2003, European journal of pharmacology.

&Dgr;9-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice

S. Nikas, A. Makriyannis, C. Paronis, 2012, Behavioural pharmacology.

Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.

S. Nikas, A. Makriyannis, J. Wood, 2021, European journal of medicinal chemistry.

Probing the Carboxyester Side Chain in Controlled Deactivation (−)-Δ8-Tetrahydrocannabinols

Rishi Sharma, S. Nikas, A. Makriyannis, 2014, Journal of medicinal chemistry.

Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans

Eugene S. Gutman, T. Prisinzano, J. Bergman, 2023, Molecules.

Apparent pA 2 Values of Benzodiazepine Antagonists and Partial Agonists in Monkeys 1

J. Bergman, C. Paronis, 1999 .

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse

K. Bui, C. Paronis, M. Pietras, 2014, Pharmacology Biochemistry and Behavior.

The Effects of Chronic Naltrexone on Reinstatement of Opioid-Induced Drug-Seeking Behavior and Antinociception.

Sarah L. Withey, C. Paronis, Jack Bergman, 2023, The Journal of pharmacology and experimental therapeutics.

Probing the Carboxyester Side Chain in Controlled Deactivation (−)-Δ8-Tetrahydrocannabinols

Rishi Sharma, S. Nikas, A. Makriyannis, 2014, Journal of medicinal chemistry.